Seasonal influenza vaccination in patients with COPD: a systematic literature review - PubMed (original) (raw)
Review
Seasonal influenza vaccination in patients with COPD: a systematic literature review
Rafik Bekkat-Berkani et al. BMC Pulm Med. 2017.
Abstract
Background: Influenza is a frequent cause of exacerbations of chronic obstructive pulmonary disease (COPD). Exacerbations are associated with worsening of the airflow obstruction, hospitalisation, reduced quality of life, disease progression, death, and ultimately, substantial healthcare-related costs. Despite longstanding recommendations to vaccinate vulnerable high-risk groups against seasonal influenza, including patients with COPD, vaccination rates remain sub-optimal in this population.
Methods: We conducted a systematic review to summarise current evidence from randomised controlled trials (RCTs) and observational studies on the immunogenicity, safety, efficacy, and effectiveness of seasonal influenza vaccination in patients with COPD. The selection of relevant articles was based on a three-step selection procedure according to predefined inclusion and exclusion criteria. The search yielded 650 unique hits of which 48 eligible articles were screened in full-text.
Results: Seventeen articles describing 13 different studies were found to be pertinent to this review. Results of four RCTs and one observational study demonstrate that seasonal influenza vaccination is immunogenic in patients with COPD. Two studies assessed the occurrence of COPD exacerbations 14 days after influenza vaccination and found no evidence of an increased risk of exacerbation. Three RCTs showed no significant difference in the occurrence of systemic effects between groups receiving influenza vaccine or placebo. Six out of seven studies on vaccine efficacy or effectiveness indicated long-term benefits of seasonal influenza vaccination, such as reduced number of exacerbations, reduced hospitalisations and outpatient visits, and decreased all-cause and respiratory mortality.
Conclusions: Additional large and well-designed observational studies would contribute to understanding the impact of disease severity and patient characteristics on the response to influenza vaccination. Overall, the evidence supports a positive benefit-risk ratio for seasonal influenza vaccination in patients with COPD, and supports current vaccination recommendations in this population.
Keywords: COPD; Effectiveness; Efficacy; Immunogenicity; Influenza; Systematic review; Vaccination.
Figures
Fig. 1
Selection of studies: databases used and criteria for exclusion (n = number of studies)
Fig. 2
a Seroconversion rate (95% Confidence interval) 4 weeks after seasonal influenza vaccination in patients with COPD (reference [mean age ± SD; range]), European Committee for Medicinal Products for Human Use (CHMP) criteria for licensure for subjects aged >60 years. b Seroprotection rate (95% Confidence interval) 4 weeks after seasonal influenza vaccination in patients with COPD (reference [age ± SD; range]), European Committee for Medicinal Products for Human Use (CHMP) criteria for licensure for subjects aged >60 years
Similar articles
- Influenza vaccine for chronic obstructive pulmonary disease (COPD).
Kopsaftis Z, Wood-Baker R, Poole P. Kopsaftis Z, et al. Cochrane Database Syst Rev. 2018 Jun 26;6(6):CD002733. doi: 10.1002/14651858.CD002733.pub3. Cochrane Database Syst Rev. 2018. PMID: 29943802 Free PMC article. Review. - Influenza vaccine for patients with chronic obstructive pulmonary disease.
Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Poole PJ, et al. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002733. doi: 10.1002/14651858.CD002733.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437444 Updated. Review. - Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness.
Sanei F, Wilkinson T. Sanei F, et al. Ther Adv Respir Dis. 2016 Aug;10(4):349-67. doi: 10.1177/1753465816646050. Epub 2016 May 18. Ther Adv Respir Dis. 2016. PMID: 27193567 Free PMC article. Review. - Influenza vaccines in immunosuppressed adults with cancer.
Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Bitterman R, et al. Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD008983. doi: 10.1002/14651858.CD008983.pub3. Cochrane Database Syst Rev. 2018. PMID: 29388675 Free PMC article. Review. - Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients.
Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Wongsurakiat P, et al. J Med Assoc Thai. 2003 Jun;86(6):497-508. J Med Assoc Thai. 2003. PMID: 12924797 Clinical Trial.
Cited by
- Influenza Vaccination in Adults in the United States with COPD before and after the COVID-19 Pandemic (2017-2022): A Multi-Year Cross-Sectional Study.
Wold M, Oancea SC. Wold M, et al. Vaccines (Basel). 2024 Aug 21;12(8):931. doi: 10.3390/vaccines12080931. Vaccines (Basel). 2024. PMID: 39204054 Free PMC article. - Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progression.
Sweef O, Mahfouz R, Taşcıoğlu T, Albowaidey A, Abdelmonem M, Asfar M, Zaabout E, Corcino YL, Thomas V, Choi ES, Furuta S. Sweef O, et al. Int J Mol Sci. 2024 Aug 19;25(16):9001. doi: 10.3390/ijms25169001. Int J Mol Sci. 2024. PMID: 39201688 Free PMC article. Review. - Impact of Smoking Cessation and Charlson Comorbidity Index on Influenza Vaccination Efficacy in COPD Patients.
Chang HC, Liu SF. Chang HC, et al. Microorganisms. 2024 Jul 16;12(7):1437. doi: 10.3390/microorganisms12071437. Microorganisms. 2024. PMID: 39065205 Free PMC article. - No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.
Naficy A, Kuxhausen A, Seifert H, Hastie A, Leav B, Miller J, Anteyi K, Mwakingwe-Omari A. Naficy A, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2327736. doi: 10.1080/21645515.2024.2327736. Epub 2024 Mar 21. Hum Vaccin Immunother. 2024. PMID: 38513689 Free PMC article. Clinical Trial.
References
- GBD Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385:117–171. doi: 10.1016/S0140-6736(14)61682-2. - DOI - PMC - PubMed
- Global Initiative for Chronic Obstructive Lung Disease (GOLD . Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease (updated 2013) 2013. - PubMed
- Kostikas K, Patalano F, Clemens A. Prediction and prevention of exacerbations and mortality in patients with COPD. Expert Rev Respir Med. 2016;10(7):739–53. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical